ORIGINAL ARTICLE
Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell
More details
Hide details
Submission date: 2016-12-16
Final revision date: 2017-05-02
Acceptance date: 2017-06-07
Publication date: 2018-03-06
Pol J Pathol 2017;68(4):312-317
KEYWORDS
TOPICS
ABSTRACT
Transforming growth factor-β (TGF-β) signaling pathways play an important role in inhibition and promotion of cell proliferation in neural stem cells (NSCs) and glioma stem/progenitor cells (GSPCs), respectively. However, the mechanisms underlying these processes remain unknown. We presumed that there may be functional inhibition at the receptor downstream of TGF-β signaling pathway leading to the activation of non- TGF-β/Smad signaling pathway, which stimulates the proliferation of GSPCs. In this study, GSPCs, from glioma cell lines SHG44, were cultivated with TGF-β receptor inhibitors (LY2157299 and LY2109761), and then the proliferative capability of GSPCs was measured; as well, the synthesis of TGF-β ligands, and the mRNA expression level of TGF-β and some key molecules of non-Smad signaling pathways were also detected. Our results showed that inhibitors against TGF-β receptors could promote the proliferation of GSPCs, and the synthesis of TGF-β ligands was enhanced. Furthermore, the inhibition of TGF-β receptor may lead to the activation of non-Smad signaling pathways (mTOR and NF-κB). In conclusion, the down-regulation of TGF-β receptor capability by TGF-β receptor inhibitors can increase TGF-β ligands synthesis and secretion, which then promote GSPCs proliferation by activating non-Smad signaling pathways.
REFERENCES (23)
1.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2.
Park CH, Bergsagel DE, McCulloch E. A mouse myeloma tumor stem cells aprimary cell culture assay. J Nat Cancer Institute 1971; 46: 411-422.
3.
Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
4.
Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
5.
Sorensen MD, Fosmark S, Hellwege S, et al. Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Adv Exp Med Biol 2015; 853: 111-138.
6.
Golestaneh N, Mishra B. TGF-beta, Neuronal Stem Cells and Glioblastoma. Oncogene 2005; 24: 5722-5730.
7.
Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through box factors. Cell Stem Cell 2009; 5: 504-514.
8.
Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, et al. TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010; 18: 655-668.
9.
Pe¼uelas S, Anido J, Prieto-Sánchez RM, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-327.
10.
Han J, Alvarez-Breckenridge CA, Wang QE, et al. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res 2015; 5: 945-955.
11.
Schneider T, Sailer M, Ansorge S, et al. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006; 79: 61-65.
12.
Zhang L, Sato E, Amagasaki K, et al. Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg 2006; 105: 119-128.
13.
Zhang QB, Ji XY, Huang Q, et al. Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. Cell res 2006; 16: 909-915.
14.
Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. Cell Biochem 2007; 102: 593-608.
15.
Inman GJ. Switching TGF from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011; 21: 93-99.
16.
Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 2016; 7: 33440-33450.
17.
Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012; 17: 205-216.
18.
Schiffer M, Mundel P, Shaw AS, et al. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279: 37004-37012.
19.
Zhu Y, Culmsee C, Klumpp S, et al. Neuroprotection by transforming growth factor-beta 1 involves activation of nuclear factor-kappa B through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1, 2 signaling pathways. Neuroscience 2004; 123: 897-906.
20.
Bharti AC, AggarwaI BB. NucIear factor-kappa B and cancer: its role in prevention and therapy. Biochem PharmacoI 2002; 64: 883-888.
21.
Freudlsperger C, Bian Y, Wise SC, et al. TGF- and NF-B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 2013; 32: 1549-1559.
22.
Gingery A, Bradley E, Shaw A, et al. TGF- Coordinately Activates TAK1/MEK/AKT/NFkB and Smad Pathways to Promote Osteoclast Survival. J Cellular Biochemistry 2003; 89: 165-179.
23.
Qiu B, Zhang D, Wang C. IL-10 and TGF-2 are overexpressed in tumor spheres cultured from human gliomas. Mol Bio Rep 2011; 38: 3585-3591.